Novacyt Stock

Novacyt Assets per Share

The Total Assets per Share of Novacyt (ALNOV.PA) as of Sep 4, 2026 is 1.00 GBP. In the previous year, Total Assets per Share was 1.89 GBP — a change of -47.22% (lower).

Assets per Share

1.00GBP

YoY

-47.22%

Last updated:

Total Assets per Share of Novacyt is 2026 1.00 GBP. Total Assets per Share of Novacyt was 2025 1.89 GBP. It decreases by -47.22% lower compared to the previous year.

The Novacyt Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2017
0.42 GBP
Jan 1, 2018
0.42 GBP
Jan 1, 2019
0.38 GBP
Jan 1, 2020
3.32 GBP
Jan 1, 2021
2.60 GBP
Jan 1, 2022
1.99 GBP
Jan 1, 2023
1.89 GBP
Jan 1, 2024
1.00 GBP
The Novacyt Assets per Share history
YEARAssets per ShareYoY
1.00GBP-47.22%
1.89GBP-5.03%
1.99GBP-23.30%
2.60GBP-21.59%
3.32GBP+783.16%
0.38GBP-9.52%
0.42GBP-0.71%
0.42GBP+12.80%
0.37GBP+53.02%
0.24GBP-35.81%
0.38GBP
Access this data via the Eulerpool API

Novacyt Stock analysis

What does Novacyt do? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novacyt stock

Total Assets per Share of Novacyt is 1.00 GBP in 2026.

Total Assets per Share of Novacyt changed from 1.89 GBP to 1.00 GBP, representing a -47.22% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share Novacyt since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

Other — Novacyt

All Key Metrics — Novacyt